Compare Gilead Sciences, Inc. (GILD) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Marathon Petroleum Corp — how do they compare? Gilead Sciences, Inc. trades at $134.63 (market cap $163.51B), while Marathon Petroleum Corp trades at $306.76 (market cap $87.34B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | MPC | |
|---|---|---|
Market Cap | $163.51B | $87.34B |
Sector | Health | Energy |
52-Week High | $155.80 | $303.40 |
52-Week Low | $108.22 | $158.59 |
Enterprise Value | $178.05B | $119.52B |
Dividend Yield | 2.49% | 1.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Marathon Petroleum (MPC) trades at $308.19, up 1.58% today, with strong technical momentum and bullish moving averages. The stock shows robust profitability with a 27.92% ROE and 3.42% net margin, though revenue has declined from $177.5B in 2022 to $132.7B in 2025. Recent news highlights refining margin strength driving outperformance, with 75.76% analyst buy ratings supporting positive sentiment.
Outlook remains favorable due to elevated refining margins and strategic upgrades, but risks include revenue declines, legal challenges from AI pricing lawsuits, and geopolitical tensions affecting oil markets. The consensus price target of $292.70 suggests modest downside from current levels despite overall bullish analyst coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
